CLINICAL RESEARCH
Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis
Kaisa M. Mäki-Petäjä, BSc*,*,
Anthony D. Booth, MD, MRCP*,
Frances C. Hall, DPhil, FRCP ,
Sharon M.L. Wallace, BA, RN*,
John Brown, DM, FRCP ,
Carmel M. McEniery, PhD* and
Ian B. Wilkinson, DM, FRCP*
* Clinical Pharmacology Unit
Department of Clinical Medicine, Addenbrooke's Hospital
Trinity College, University of Cambridge, Cambridge, United Kingdom
Manuscript received February 6, 2007;
revised manuscript received April 20, 2007,
accepted April 22, 2007.
* Reprint requests and correspondence: Kaisa Mäki-Petäjä, Clinical Pharmacology Unit, University of Cambridge, Addenbrooke's Hospital, BOX 110, Cambridge CB2 0QQ, United Kingdom. (Email: km391{at}cam.ac.uk).
Objectives: The aim of this study was to investigate the effect of simvastatin and ezetimibe on inflammation, disease activity, endothelial dysfunction, and arterial stiffness in a cohort of rheumatoid arthritis (RA) patients.
Background: Rheumatoid arthritis is a chronic inflammatory condition associated with increased cardiovascular risk. Statins reduce inflammation and disease activity in RA patients, but whether this is due to pleiotropism or cholesterol lowering per se is unclear.
Methods: Twenty patients received 20 mg simvastatin or 10 mg ezetimibe each for 6 weeks in a randomized double-blind crossover study. Disease activity, blood pressure, aortic pulse wave velocity (PWV), brachial artery flow-mediated dilation (FMD), and serum inflammatory markers were measured before and after each treatment.
Results: Both ezetimibe and simvastatin significantly reduced total cholesterol (–0.62 ± 0.55 mmol/l and –1.28 ± 0.49 mmol/l, respectively; p < 0.001), low-density lipoprotein cholesterol (–0.55 ± 0.55 mmol/l and –1.28 ± 0.49 mmol/l; p < 0.0001), and C-reactive protein (–5.35 ± 9.25 mg/l and –5.05 ± 6.30 mg/l; p < 0.001). Concomitantly, Disease Activity Score (–0.55 ± 1.01 and –0.67 ± 0.91; p = 0.002), aortic PWV (–0.69 ± 1.15 m/s and –0.71 ± 0.71 m/s; p = 0.001), and FMD (1.37 ± 1.17% and 2.51 ± 2.13%; p = 0.001) were significantly improved by both drugs.
Conclusions: This study demonstrates that both ezetimibe and simvastatin reduce disease activity and inflammatory markers to a similar extent in patients with RA. Therapy is also associated with a concomitant reduction in aortic PWV and improvement in endothelial function. This suggests that cholesterol lowering per se has anti-inflammatory effects and improves vascular function in RA.
|
Abbreviations and Acronyms
| | AIx = augmentation index | | CRP = C-reactive protein | | DAS = Disease Activity Score | | ESR = erythrocyte sedimentation rate | | FMD = flow-mediated dilatation | | GTN = glyceryl trinitrate | | oxLDL = oxidized low-density lipoprotein | | PWV = pulse wave velocity | | RA = rheumatoid arthritis |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 50: A31-A32.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
X. SHENG, M. J. MURPHY, T. M. MacDONALD, and L. WEI
Effectiveness of Statins on Total Cholesterol and Cardiovascular Disease and All-cause Mortality in Osteoarthritis and Rheumatoid Arthritis
J Rheumatol,
January 1, 2012;
39(1):
32 - 40.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sandoo, J. J. C. S. Veldhuijzen van Zanten, G. S. Metsios, D. Carroll, and G. D. Kitas
Vascular function and morphology in rheumatoid arthritis: a systematic review
Rheumatology,
November 1, 2011;
50(11):
2125 - 2139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-T. Tang, Y. Song, Y.-J. Ding, Y.-H. Liao, X. Yu, R. Du, H. Xiao, J. Yuan, Z.-H. Zhou, M.-Y. Liao, et al.
Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis
J. Lipid Res.,
May 1, 2011;
52(5):
1023 - 1032.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. EL-BARBARY, M. S. HUSSEIN, E. M. RAGEH, H. E. HAMOUDA, A. A. WAGIH, and R. G. ISMAIL
Effect of Atorvastatin on Inflammation and Modification of Vascular Risk Factors in Rheumatoid Arthritis
J Rheumatol,
February 1, 2011;
38(2):
229 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Semb, I. Holme, T. K. Kvien, and T. R. Pedersen
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial
Rheumatology,
February 1, 2011;
50(2):
324 - 329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Charakida, S. Masi, T. F. Luscher, J. J. P. Kastelein, and J. E. Deanfield
Assessment of atherosclerosis: the role of flow-mediated dilatation
Eur. Heart J.,
December 1, 2010;
31(23):
2854 - 2861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Takumi, E. H. Yang, V. Mathew, C. S. Rihal, R. Gulati, L. O. Lerman, and A. Lerman
Coronary endothelial dysfunction is associated with a reduction in coronary artery compliance and an increase in wall shear stress
Heart,
May 1, 2010;
96(10):
773 - 778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. CRILLY, H. J. CLARK, V. KUMAR, N. W. SCOTT, A. G. MacDONALD, and D. J. WILLIAMS
Relationship Between Arterial Stiffness and Stanford Health Assessment Questionnaire Disability in Rheumatoid Arthritis Patients without Overt Arterial Disease
J Rheumatol,
May 1, 2010;
37(5):
946 - 952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Vivodtzev, C. Minet, B. Wuyam, J.-C. Borel, G. Vottero, D. Monneret, J.-P. Baguet, P. Levy, and J.-L. Pepin
Significant Improvement in Arterial Stiffness After Endurance Training in Patients With COPD
Chest,
March 1, 2010;
137(3):
585 - 592.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M J L Peters, D P M Symmons, D McCarey, B A C Dijkmans, P Nicola, T K Kvien, I B McInnes, H Haentzschel, M A Gonzalez-Gay, S Provan, et al.
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
Ann Rheum Dis,
February 1, 2010;
69(2):
325 - 331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Angel, S. A. Provan, H. L. Gulseth, P. Mowinckel, T. K. Kvien, and D. Atar
Tumor Necrosis Factor-{alpha} Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies: A Controlled Study
Hypertension,
February 1, 2010;
55(2):
333 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Sluijs, Y. Plantinga, B. de Roos, L. I Mennen, and M. L Bots
Dietary supplementation with cis-9,trans-11 conjugated linoleic acid and aortic stiffness in overweight and obese adults
Am J Clin Nutr,
January 1, 2010;
91(1):
175 - 183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bass, A. L Hinderliter, and C. R Lee
The Impact of Ezetimibe on Endothelial Function and Other Markers of Cardiovascular Risk
Ann. Pharmacother.,
December 1, 2009;
43(12):
2021 - 2030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Crilly, V. Kumar, H. J. Clark, N. W. Scott, A. G. MacDonald, and D. J. Williams
Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a dose-response relationship independent of established cardiovascular risk factors
Rheumatology,
December 1, 2009;
48(12):
1606 - 1612.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Helmers, D. C. Gowda, K. C. Kain, and W. C. Liles
Statins Fail to Improve Outcome in Experimental Cerebral Malaria and Potentiate Toll-Like Receptor-Mediated Cytokine Production by Murine Macrophages
Am J Trop Med Hyg,
October 1, 2009;
81(4):
631 - 637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. C. Burghuber and A. Valipour
Knowing Chronic Obstructive Pulmonary Disease by Heart: Cumulating Evidence of Systemic Vascular Dysfunction
Am. J. Respir. Crit. Care Med.,
September 15, 2009;
180(6):
487 - 488.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Tershakovec, E. P. Veltri, and R. C. Pasternak
Letter by Tershakovec et al Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation"
Circulation,
September 1, 2009;
120(9):
e67 - e67.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Settergren, L. Ryden, and J. Pernow
Letter by Settergren et al Regarding Article, "Evidence for Statin Pleiotropy in Humans: Differential Effects of Statins and Ezetimibe on Rho-Associated Coiled-Coil Containing Protein Kinase Activity, Endothelial Function, and Inflammation"
Circulation,
September 1, 2009;
120(9):
e68 - e68.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Recio-Mayoral, J. C. Mason, J. C. Kaski, M. B. Rubens, O. A. Harari, and P. G. Camici
Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease
Eur. Heart J.,
August 1, 2009;
30(15):
1837 - 1843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Kuhl
Hypertrophic Cardiomyopathy, Fibrosis, and Aortic Stiffness: An Unidentified Association Unraveled by Magnetic Resonance Imaging
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
263 - 264.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Semb, S. Provan, T. Kvien, and T. Pedersen
Effect of high-intensity statin treatment in rheumatoid arthritis: a case with possible coronary atheroma regression and progression of rheumatoid valve degeneration
BMJ Case Reports,
June 21, 2009;
2009(jun21_1):
bcr0820080717 - bcr0820080717.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Montecucco, F. Burger, G. Pelli, N. K. Poku, C. Berlier, S. Steffens, and F. Mach
Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes
Rheumatology,
March 1, 2009;
48(3):
233 - 242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. P. Bruce
Recent Developments in the Treatment of Rheumatoid Arthritis
Journal of Pharmacy Practice,
February 1, 2009;
22(1):
65 - 74.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. F. Panoulas, G. S. Metsios, A. V. Pace, H. John, G. J. Treharne, M. J. Banks, and G. D. Kitas
Hypertension in rheumatoid arthritis
Rheumatology,
September 1, 2008;
47(9):
1286 - 1298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kinlay
Vascular form and function: two mechanisms for cardiovascular prevention
Eur. Heart J.,
July 2, 2008;
29(14):
1711 - 1713.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. TAYLOR
Given the ENHANCE trial results, ezetimibe is still unproven
Cleveland Clinic Journal of Medicine,
July 1, 2008;
75(7):
497 - 506.
[Full Text]
[PDF]
|
|
|
|
